Abstract
Aim: Efficacy of intermittent palonosetron dosing in patients undergoing multiple-day, high-dose chemotherapy (HDC) was investigated. Patients & methods: Fifty-eight patients received palonosetron (0.25 mg intravenous [iv.]) every other day plus daily dexamethasone (8 mg iv. twice daily) dosing. The primary end point was complete control (CC; no emesis, no rescue anti-emetics, and no more than mild nausea) in the overall acute-period (until 24 h after chemotherapy completion). Results: Acute-period CC occurred in 81% and 50% of patients receiving palonosetron and ondansetron (historical control cohort), respectively. Palonosetron (odds ratio [OR]: 4.37; p = 0.001) and a longer duration of HDC regimen (OR: 3.47; p = 0.011) independently predicted a better anti-emetic outcome. Conclusion: Palonosetron every other day plus daily dexamethasone is an effective anti-emetic coverage in patients undergoing HDC.
| Original language | English |
|---|---|
| Pages (from-to) | 2569-2578 |
| Number of pages | 10 |
| Journal | Future Oncology |
| Volume | 10 |
| Issue number | 16 |
| DOIs | |
| Publication status | Published - Dec 1 2014 |
Fingerprint
Keywords
- CINV
- dexamethasone
- high-dose chemotherapy
- nausea
- vomiting
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy. / Mirabile, Aurora; Celio, Luigi; Magni, Michele; Bonizzoni, Erminio; Gianni, Alessandro Massimo; Di Nicola, Massimo.
In: Future Oncology, Vol. 10, No. 16, 01.12.2014, p. 2569-2578.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy
AU - Mirabile, Aurora
AU - Celio, Luigi
AU - Magni, Michele
AU - Bonizzoni, Erminio
AU - Gianni, Alessandro Massimo
AU - Di Nicola, Massimo
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Aim: Efficacy of intermittent palonosetron dosing in patients undergoing multiple-day, high-dose chemotherapy (HDC) was investigated. Patients & methods: Fifty-eight patients received palonosetron (0.25 mg intravenous [iv.]) every other day plus daily dexamethasone (8 mg iv. twice daily) dosing. The primary end point was complete control (CC; no emesis, no rescue anti-emetics, and no more than mild nausea) in the overall acute-period (until 24 h after chemotherapy completion). Results: Acute-period CC occurred in 81% and 50% of patients receiving palonosetron and ondansetron (historical control cohort), respectively. Palonosetron (odds ratio [OR]: 4.37; p = 0.001) and a longer duration of HDC regimen (OR: 3.47; p = 0.011) independently predicted a better anti-emetic outcome. Conclusion: Palonosetron every other day plus daily dexamethasone is an effective anti-emetic coverage in patients undergoing HDC.
AB - Aim: Efficacy of intermittent palonosetron dosing in patients undergoing multiple-day, high-dose chemotherapy (HDC) was investigated. Patients & methods: Fifty-eight patients received palonosetron (0.25 mg intravenous [iv.]) every other day plus daily dexamethasone (8 mg iv. twice daily) dosing. The primary end point was complete control (CC; no emesis, no rescue anti-emetics, and no more than mild nausea) in the overall acute-period (until 24 h after chemotherapy completion). Results: Acute-period CC occurred in 81% and 50% of patients receiving palonosetron and ondansetron (historical control cohort), respectively. Palonosetron (odds ratio [OR]: 4.37; p = 0.001) and a longer duration of HDC regimen (OR: 3.47; p = 0.011) independently predicted a better anti-emetic outcome. Conclusion: Palonosetron every other day plus daily dexamethasone is an effective anti-emetic coverage in patients undergoing HDC.
KW - CINV
KW - dexamethasone
KW - high-dose chemotherapy
KW - nausea
KW - vomiting
UR - http://www.scopus.com/inward/record.url?scp=84910033052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84910033052&partnerID=8YFLogxK
U2 - 10.2217/fon.14.132
DO - 10.2217/fon.14.132
M3 - Article
C2 - 24947121
AN - SCOPUS:84910033052
VL - 10
SP - 2569
EP - 2578
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 16
ER -